Bombesin-Targeted PET of Prostate Cancer

Mansi, Rosalba; Minamimoto, Ryogo; Mäcke, Helmut R.; Iagaru, Andrei

doi:10.2967/jnumed.115.170977

Cited by 48 publications

(46 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Las investigaciones más recientes se han centrado en éstos, pero marcados con radionúclidos como el 68Ga y el 64Cu, agentes para PET/CT 21 .…”

Section: A B Cunclassified

Radiotrazadores empleados en medicina nuclear para el diagnóstico y seguimiento del cáncer de próstata

García-Pérez¹,

Medina-Ornelas²

2022

GAMO

View full text Add to dashboard Cite

Resumen El cáncer de próstata (CP) es la causa más común de cáncer en hombres a nivel mundial. Actualmente, la imagen en el CP ha tomado una gran importancia para la estadificación, reestadificación, selección del tratamiento y evaluación de la recurrencia. La imagen molecular con tomografía por emisión de positrones (PET) ha permitido un enfoque personalizado para estos propósitos. Además de estas necesidades clínicas, existe una creciente visión y reto para las nuevas técnicas de imagen molecular, no sólo para detectar la enfermedad metastásica, sino también para proporcionar información importante acerca de la biología tumoral, el pronóstico y, uno de los retos más grandes de las técnicas de imagen no radioisotópicas, la detección de recurrencia en pacientes con niveles bajos de antígeno prostático específico (APE). (creativecommons.org/licenses/by-nc-nd/4.0/). ARTÍCULO DE REVISIÓNRadiotrazadores empleados en medicina nuclear para el diagnóstico y seguimiento del cáncer de próstata

show abstract

“…Las investigaciones más recientes se han centrado en éstos, pero marcados con radionúclidos como el 68Ga y el 64Cu, agentes para PET/CT 21 .…”

Section: A B Cunclassified

Radiotrazadores empleados en medicina nuclear para el diagnóstico y seguimiento del cáncer de próstata

García-Pérez¹,

Medina-Ornelas²

2022

GAMO

View full text Add to dashboard Cite

show abstract

“…Prior studies have shown high binding affinity of agonists to GRPRs, and their subsequent cell internalization was believed to enhance the uptake, because the radioactivity was trapped in the intracellular compartment. However, other studies proved that antagonists are superior to agonists, because of their considerably higher binding affinity to the GRPR (77,78). One of the most investigated radioantagonists for PCa imaging is statine-based JMV594 ( D Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH 2 ), first designed by Llinares et al (79) and then modified.…”

Section: Bombesin/gastrin-releasing Peptidementioning

confidence: 99%

Positron emission tomography (PET) in primary prostate cancer staging and risk assessment

Bednarova

Lindenberg

Vinsensia

et al. 2017

Transl. Androl. Urol.

View full text Add to dashboard Cite

Prostate cancer (PCa) is one of the few neoplasms that are not well served by 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET). As a result, a number of PET tracers have been developed to target particular biological features of PCa. Such agents can be used for diagnosis, staging, identification of biochemical recurrence (BCR) and evaluation of metastatic disease. Here, we focus on primary disease and local staging. To date, magnetic resonance imaging (MRI) has proven superior to PET in the imaging of primary PCa. However, some PET agents have shown remarkable promise in staging high-risk PCa (defined as any combination of a clinical T3, a PSA score >20 ng/mL, or a Gleason score of 8–10), as well as biochemical relapse after definitive therapy and metastatic PCa. PET agents can be divided into those that interrogate tumor metabolism (18F-FDG, 11C-Choline, 18F-Choline, 11C-Acetate, 18F-FACBC), hormone receptors (18F-FDHT), and other targets such as prostate specific membrane antigen (PSMA) (68Ga-PSMA, 18F-DCFBC, 18F-DCFPyl) or gastric releasing peptide (18F-GRP or 18F-Bombesin). In this review, we compare the available PCa targeted PET tracers utilized in staging of high risk tumors.

show abstract

“…Most recent investigations have focused on these agents for PET/ CT, but marked with radionuclides such as 68Ga and 64Cu 21 .…”

Section: Mtc-bombesinmentioning

confidence: 99%

“…In males, it is at first place, with 21.4% of all newly diagnosed tumors 1,2 . Imaging plays an important role in PC, including accurate evaluation of disease extension, assessment of the site of recurrence, and monitoring of treatment response.…”

Section: Introductionmentioning

confidence: 99%

Radiotracers Used in Nuclear Medicine for Prostate Cancer Diagnosis and Follow-Up

García-Pérez¹,

Medina-Ornelas²

2022

GAMO

View full text Add to dashboard Cite

Prostate cancer is the most common cause of cancer in males worldwide. Currently, imaging in prostate cancer has acquired great importance in staging, re-staging, treatment selection, and recurrence assessment. Molecular imaging with positron-emission tomography has enabled a personalized approach for these purposes. In addition to these clinical needs, there are growing perspectives and a challenge for new molecular imaging techniques, not only to detect metastatic disease, but also to provide relevant information on tumor biology and prognosis, and one of the greatest challenges for non-radioisotope imaging techniques is the ability to detect recurrence in patients with low levels of prostate-specific antigen. (creativecommons.org/licenses/by-nc-nd/4.0/).

show abstract

Bombesin-Targeted PET of Prostate Cancer

Cited by 48 publications

References 58 publications

Radiotrazadores empleados en medicina nuclear para el diagnóstico y seguimiento del cáncer de próstata

Radiotrazadores empleados en medicina nuclear para el diagnóstico y seguimiento del cáncer de próstata

Positron emission tomography (PET) in primary prostate cancer staging and risk assessment

Radiotracers Used in Nuclear Medicine for Prostate Cancer Diagnosis and Follow-Up

Contact Info

Product

Resources

About